Market revenue in 2022 | USD 7,762.0 million |
Market revenue in 2030 | USD 12,574.7 million |
Growth rate | 6.2% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Estrogen and Progesterone Replacement Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 54.69% in 2022. Horizon Databook has segmented the U.S. hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. hormone replacement therapy market generated the largest revenue share in North America in 2021. Economic stability of the country and supportive reimbursement policies are contributing to the adoption of expensive therapies.
Better healthcare infrastructure and reimbursement policies are expected to increase the adoption of hormone replacement therapies in the coming years. For instance, around 25% of children receive insurance coverage under the Children's Health Insurance Program (CHIP) for GHD.
However, the percentage of patients with GHD covered under Medicaid is higher than private insurers. According to American Thyroid Association (ATA), thyroid disorders are common conditions in the U.S. More than 12.0% of the population suffers from these conditions in their lifetime.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into U.S. hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account